CD7 and synovial sarcoma: Targeting CD2, therefore, would allow for the effective targeting of a wide variety of CD7 negative or low expression T cell leukemia and lymphomas such as T-ALL, SS, peripheral T cell malignancies, and adult T cell leukemia/lymphoma (ATL).